Personalized Care in CLL: Treatment Pathway for Younger vs Older Pts, Summary of Major Studies With BTKi Ibrutinib and Acalabrutinib

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Personalized Care in CLL: Treatment Pathway for Younger vs Older Pts, Summary of Major Studies With BTKi Ibrutinib and Acalabrutinib

By PeerView Oncology FEATURING Ryan Jacobs

238 views

March 26, 2020

For the complete PeerView activity, and to receive CME credit or download slides and educational ...
read more ↘ materials, please access this link: www.PeerView.com/RZK
↖ read less

0 Comments

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale